Related Experiment Videos
Comparison of two quantitative hepatitis C virus reverse transcriptase PCR assays
Journal of Clinical Microbiology
|February 1, 1996
Summary
A new hepatitis C virus reverse transcriptase PCR (HCV RT-PCR) assay shows agreement with the Roche Amplicor kit for low viral loads. High viral loads revealed significant differences between the two quantitative HCV RNA detection methods.
Area of Science:
- Virology
- Molecular Biology
- Clinical Diagnostics
Background:
- Accurate quantification of hepatitis C virus (HCV) RNA is crucial for patient management and treatment monitoring.
- Existing quantitative assays, such as the Roche Amplicor HCV Monitor test kit, are widely used but may have limitations in detecting high viral loads.
Purpose of the Study:
- To compare the performance of a newly developed in-house quantitative HCV reverse transcriptase PCR (HCV RT-PCR) assay against the Roche Amplicor HCV Monitor test kit.
- To evaluate agreement in test results and assess intra-assay variability for both quantitative HCV RNA detection methods.
Main Methods:
- Both assays utilized reverse transcription and PCR amplification of extracted RNA from patient serum samples.
- An internal RNA standard derived from the 5'-noncoding region of HCV was incorporated into both methods.
- A panel of 33 clinical serum samples was analyzed in parallel using the in-house HCV RT-PCR and the Roche Amplicor HCV Monitor test kit.
Main Results:
- Substantial agreement was observed between the two methods for HCV RNA levels ranging from 1 x 10(3) to 5 x 10(5) molecules/ml.
- Significant discrepancies, up to 2 orders of magnitude, were noted for samples with viral loads exceeding 5 x 10(5) copies/ml as determined by the in-house assay.
- The in-house assay detected up to 5 x 10(7) HCV RNA molecules/ml, while the Roche kit's upper limit of detection was 2 x 10(6) molecules/ml.
- Dilution of high-titer samples improved Roche kit's detection by approximately 0.5 orders of magnitude.
Conclusions:
- The in-house HCV RT-PCR assay demonstrates comparable performance to the Roche Amplicor HCV Monitor test kit for quantifying low to moderate HCV RNA levels.
- The in-house assay offers a wider dynamic range for detecting high viral loads, potentially providing more accurate quantification in patients with high viremia.
- Further validation is warranted, but the in-house assay shows promise for improved quantitative detection of hepatitis C virus RNA.